• USA Home
  • P9623 - Paroxetine hydrochloride hemihydrate

EMAIL THIS PAGE TO A FRIEND
P9623 Sigma-Aldrich

Paroxetine hydrochloride hemihydrate

≥98% (HPLC), powder

Synonym: (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride hemihydrate, Paroxetine HCl

  • CAS Number 110429-35-1

  • Empirical Formula (Hill Notation) C19H20FNO3 · HCl · .5 H2O

  • Molecular Weight 374.83

  •  MDL number MFCD03658863

  •  PubChem Substance ID 24278249

Purchase

Properties

Related Categories Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Bioactive Small Molecules, Biochemicals and Reagents, Biogenic Amine Transport Inhibitors,
Quality Level   100
assay   ≥98% (HPLC)
form   powder
color   white
originator   GlaxoSmithKline
SMILES string   O.Cl[H].Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3
InChI   1S/C19H20FNO3.ClH.H2O/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;;/h1-6,9,14,17,21H,7-8,10-12H2;1H;1H2/t14-,17-;;/m0../s1
InChI key   QRQSGFFISBKLMZ-YHOFXEKLSA-N
Gene Information   human ... SLC6A4(6532)

Description

Application

Paroxetine hydrochloride hemihydrate has been used: as an antidepressant to study its effects on neural stem cells (NSCs) from embryonic rat hippocampus in vitro; as a CYP 2D6 inhibitor to study its effects on the in vitro production by human recombinant CYP 2D6 of the phenolic metabolites; as an antidepressant to study its effects on the expression of pituitary adenylate cyclase activating polypeptide (PACAP), its receptors and brain-derived neurotrophic factor (BDNF) in rat primary hippocampal neurons

Packaging

10, 50 mg in glass bottle

Biochem/physiol Actions

Paroxetine hydrochloride hemihydrate is one of the most potent and selective of the selective serotonin reuptake inhibitors (SSRI); antidepressant

Paroxetine is a phenylpiperidine derivative. It has the ability to cross placenta. Paroxetine is known to increase the risk of congenital cardiac malformations. It might be useful in hormone replacement therapy for treating vasomotor symptoms during menopause. It is known to ameliorate the effects of panic disorder, obsessive‐compulsive disorder and social phobia.

Features and Benefits

This compound is also offered as part of Sigma′s Library of Pharmacologically Active Compounds (LOPAC®1280), a biologically annotated collection of high-quality, ready-to-screen compounds. Click here to learn more.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold with the permission of GlaxoSmithKline

LOPAC is a registered trademark of Sigma-Aldrich Co. LLC

Safety & Documentation

Safety Information

Symbol 
Signal word 
Warning
Hazard statements 
Precautionary statements 
Personal Protective Equipment 
RIDADR 
UN 3077 9 / PGIII
WGK Germany 
WGK 3
Flash Point(F) 
Not applicable
Flash Point(C) 
Not applicable

Documents

Certificate of Analysis (COA)

Please Enter a Lot Number

Certificate of Origin (COO)

Please Enter a Lot Number
Protocols & Articles
Peer-Reviewed Papers
15

References

Related Products

Technical Service:

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Bulk Ordering & Pricing:

Need larger quantities for your development, manufacturing or research applications?